Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki‐67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine‐treated prostate cancer

Study Type – Prognosis (case series)

[1]  T. Ecke,et al.  Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability , 2008, World Journal of Urology.

[2]  A. Ruifrok,et al.  Quantification of histochemical staining by color deconvolution. , 2001, Analytical and quantitative cytology and histology.

[3]  Jorma Isola,et al.  The Application of JPEG2000 in Virtual Microscopy , 2009, Journal of Digital Imaging.

[4]  L. Egevad,et al.  Correlation of modified Gleason grading with pT stage of prostatic carcinoma after radical prostatectomy. , 2008, Analytical and quantitative cytology and histology.

[5]  Michel Bolla,et al.  [EAU guidelines on prostate cancer]. , 2009, Actas urologicas espanolas.

[6]  A. Billis.  Does perineural invasion on prostate biopsy predict adverse prostatectomy outcomes , 2009 .

[7]  M. Regan,et al.  Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. , 2004, The Journal of urology.

[8]  M. Kattan,et al.  Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. , 2001, Human pathology.

[9]  L. Dillon.  The Gene , 1987, Springer US.

[10]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[11]  T. Visakorpi,et al.  Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy , 1991, British Journal of Cancer.

[12]  M. Rubin,et al.  Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. , 2002, Urology.

[13]  S. Dosso,et al.  Docetaxel in the management of prostate cancer: current standard of care and future directions , 2008 .

[14]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[15]  B. Delahunt,et al.  Parameters of perineural invasion in radical prostatectomy specimens lack prognostic significance , 2008, Modern Pathology.

[16]  Vilppu J Tuominen,et al.  ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 , 2010, Breast Cancer Research.

[17]  M. Osaki,et al.  High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. , 2009, Oral oncology.

[18]  T. Shiraishi,et al.  Prognostic Significance of Ki–67 Expression in Advanced Prostate Cancers in Relation to Disease Progression after Androgen Ablation , 2000, European Urology.

[19]  I. Thompson,et al.  Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. , 2005, Journal of the National Cancer Institute.

[20]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[22]  Alan W Partin,et al.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.

[23]  J. Epstein,et al.  Clinical implications of changing definitions within the Gleason grading system , 2010, Nature Reviews Urology.

[24]  E. Klein,et al.  Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer , 2009, BJU international.

[25]  J. Martínez-Jabaloyas,et al.  Percentage of Cancer in Prostate Biopsies as Prognostic Factor for Staging and Postoperative Biochemical Failure after Radical Prostatectomy , 2007, Urologia Internationalis.

[26]  Dirk F Moore,et al.  Survival following primary androgen deprivation therapy among men with localized prostate cancer. , 2008, JAMA.

[27]  T. Tammela,et al.  EZH2, Ki‐67 and MCM7 are prognostic markers in prostatectomy treated patients , 2008, International journal of cancer.

[28]  Pierre I Karakiewicz,et al.  Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. , 2009, The Journal of urology.

[29]  T. Tammela,et al.  Biological aggressiveness of prostate cancer in the Finnish screening trial , 2009, International journal of cancer.

[30]  M. Hammond,et al.  Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Tseng,et al.  MCM7 amplification and overexpression are associated with prostate cancer progression , 2006, Oncogene.

[32]  E. Kulinskaya,et al.  The total percentage of biopsy cores with cancer improves the prediction of pathological stage after radical prostatectomy , 2004, BJU international.

[33]  T. Tammela,et al.  PSA Decline Is an Independent Prognostic Marker in Hormonally Treated Prostate Cancer , 1999, European Urology.

[34]  J. Simon,et al.  Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.

[35]  L. Egevad,et al.  Modified Gleason grading. An updated review. , 2009, Histology and histopathology.

[36]  M. Kattan,et al.  Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Osaki,et al.  High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. , 2009, Oral oncology.

[38]  Jing Ma,et al.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Yue Fan,et al.  Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade , 2010, BJU international.

[40]  N. Lee,et al.  Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. , 2000, International journal of radiation oncology, biology, physics.

[41]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[42]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[43]  James A Hanley,et al.  13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. , 2007, The Journal of urology.

[44]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[45]  K. Yanagihara,et al.  Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer , 2006, Cancer science.

[46]  J. Nelson,et al.  MCM7 interacts with androgen receptor. , 2008, The American journal of pathology.

[47]  D. Penson,et al.  Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. , 2007, The Journal of urology.

[48]  Tapio Visakorpi,et al.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.

[49]  M. Cooperberg,et al.  Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Athanase Billis,et al.  The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. , 2008, The Journal of urology.

[51]  D. Song,et al.  Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy. , 2007, Urology.

[52]  D. Bostwick,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. , 2001, Human pathology.

[53]  H. Moch,et al.  Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small‐volume or low‐grade prostate cancer , 2009, International journal of cancer.

[54]  J. Epstein,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. , 2001, Human pathology.

[55]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  H. Moch,et al.  Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. , 1998, Human pathology.

[57]  Tony J Collins,et al.  ImageJ for microscopy. , 2007, BioTechniques.

[58]  Michael W Kattan,et al.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Alan W Partin,et al.  Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? , 2002, The Journal of urology.